背景:急性冠脉综合征(ACS)是冠心病的常见临床切入点。法国是大麻使用率最高的欧洲国家,严重的心血管并发症也有所增加,包括梗塞,与大麻有关。主要目的是根据暴露于大麻的情况比较ACS患者的临床和心脏病学特征。
方法:我们进行了回顾性研究,单中心,2012年1月1日至2021年12月31日在Troyes医院中心接受ICUACS的所有成年患者(>18岁)的暴露-非暴露队列研究,医疗记录中提到了大麻的使用。进行匹配,以便暴露组中确定的每位患者与年龄相当的未暴露患者相关联,性别,住院期间和心血管事件类型(ACS类型和ST+的地形图)。
结果:从2012年1月1日至2021年12月31日,入住ICU和冠状动脉造影室的2745例患者在CHT出现ST+或ST-ACS。其中31名患者(1.1%),我们注意到大麻消费,其中涉及年龄在50岁以下的SCAST+的7.9%。
结论:建立了大麻使用与ACS之间的联系,但是在法国,关于大麻在ICUACS途径中的位置的研究很少。我们的结果表明,在ACS后管理中,有兴趣开发针对患者需求及其特异性的特定途径。
BACKGROUND: Acute coronary syndrome (ACS) is the usual clinical entry point for coronary heart disease. France is the European country with the highest prevalence of cannabis use and an increase in serious cardiovascular complications, including infarction, related to cannabis. The main objective was to compare the clinical and cardiological profile of patients with ACS according to exposure to cannabis use.
METHODS: We conducted a retrospective, single-centre, exposure-non-exposure cohort study of all adult patients (> 18 years) admitted for ACS in the ICU between January 1, 2012 and December 31, 2021 at the Centre Hospitalier de Troyes, with mention of cannabis use in the medical record. A matching was performed so that each patient identified in the exposed group was associated with a comparable unexposed patient on age, sex, period of hospitalisation and cardiovascular event typology (type of ACS and topography for ST+).
RESULTS: 2745 patients admitted to the ICU and the coronary angiography room presented an ST+ or ST- ACS from 01/01/2012 to 31/12/2021 at the CHT. For 31 patients of them (1.1%), we noted cannabis consumption, which concern 7,9% of SCA ST+ aged under 50.
CONCLUSIONS: The link between cannabis use and ACS is established, but studies concerning the place of cannabis in the ACS pathway of an ICU are few in France. Our results show the interest of developing a specific pathway focused on the needs of patients and their specificities in post ACS management.